# US 2019/0376051 A1 · Permanent gene correction by means of nucleotide-modified messenger rna

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0376051 A1
- Document ID: US20190376051A1
- Status: Published application
- Kind: A1
- Application number: 16/399,708
- Filed: 2019-04-30
- Published: 2019-12-12
- Earliest claimed: 2013-10-08
- Assignees: Eberhard Karls Universität Tübingen Medizinische Fakultät; Helmholtz-Zentrum für Infektionsforschung GmbH für das Helmholtz-Institut für Pharmazeutische
- Applicants: Eberhard Karls Universität Tübingen Medizinische Fakultät; Helmholtz-Zentrum für Infektionsforschung GmbH für das Helmholtz-Institut für Pharmazeutische Forsch
- Inventors: Michael KORMANN; Lauren Mays WEDDLE; Claus-Michael LEHR; Brigitta LORETZ; Emad MALAEKSEFAT
- Web page: https://patentgrep.com/patent/US20190376051A1

## CPC

- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- C12N 15/115: Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}
- C07K 14/4712: {Cystic fibrosis}
- C07K 14/785: Alveolar surfactant peptides; Pulmonary surfactant peptides
- C12N 2310/16: Aptamers
- C12N 2310/3341: 5-Methylcytosine
- C12N 2310/335: Modified T or U
- C12N 2310/3519: Fusion with another nucleic acid
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to a nucleotide-modified messenger RNA for the permanent correction of a genetic alteration on a DNA. The invention further relates to a nucleotide-modified messenger RNA in combination with a repair template. It also relates to a pharmaceutical composition. It finally relates to methods for the correction of a genetic alteration on a DNA.

## Claims

### Claim 1

A nuclease-encoding nucleotide-modified messenger RNA (nec-mRNA) configured for preconditioning the correction of a genetic alteration on a DNA, wherein in the nec-mRNA up to including approx. 50% of the uridine nucleotides and up to including approx. 50% of the cytidine nucleotides are modified by exchanging uridine for 2-thiouridine (s2U) or pseudouridine (ψ), and by exchanging cytidine for 5-methylcytidine (m5C).

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The nec-mRNA of claim 1, wherein the genetic alteration exists in a lung protein.

### Claim 4 (depends on 3)

The nec-mRNA of claim 3, wherein the genetic alteration exists in a surfactant protein.

### Claim 5 (depends on 4)

The nec-mRNA of claim 4, wherein the genetic alteration exists in a lung protein selected from the group consisting of surfactant protein B (SP-B), cystic fibrosis transmembrane and conductance regulator (CFTR), and Foxp3.

### Claim 6 (depends on 1)

The nec-mRNA of claim 1, wherein the nuclease is configured in such a way that it can bind upstream or downstream of the genetic alteration on the DNA.

### Claim 7 (depends on 1)

The nec-mRNA of claim 1, wherein the nuclease is selected from the group consisting of: zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALEN), CRISPR/Cas9, and dimeric CRISPR RNA guided Fokl nucleases.

### Claim 8 (depends on 1)

The nec-mRNA of claim 1, wherein the nec-mRNA is coupled to an aptamer.

### Claim 9 (depends on 1)

The nec-mRNA of claim 1, wherein the nec-mRNA is packed into a nanoparticle.

### Claim 10 (depends on 9)

The nec-mRNA of claim 9, wherein the nanoparticle is coated with chitosan.

### Claim 11 (depends on 1)

The nec-mRNA of claim 1 associated with a repair template.

### Claim 12 (depends on 11)

The nec-mRNA of claim 11, wherein the repair template comprises a nucleotide section which is exchangeable by homologous recombination (HR) against a section on the DNA comprising the genetic alteration.

### Claim 13 (depends on 12)

The nec-mRNA of claim 12, wherein the repair template is one of the following: packed into an adeno-associated viral vector (AAV), encoded by a plasmid DNA, packed into a lentiviral vector, and packed into a protein-capped adenoviral vector (AdV).

### Claim 14 (depends on 1)

A pharmaceutical composition comprising the nuclease-encoding nucleotide-modified messenger RNA (nec-mRNA) of claim 1.

### Claim 15 (depends on 14)

The pharmaceutical composition of claim 14, which further comprises a repair template.

### Claim 16 (depends on 15)

The pharmaceutical composition of claim 15 that is configured for the treatment of a lung disease selected from the group consisting of: surfactant protein B deficiency, cystic fibrosis (CF), asthma, and chronic obstructive pulmonary disease (COPD).

### Claim at position 17

17-18. (canceled)

### Claim 19 (depends on 1)

A method for the correction of a genetic alteration on a DNA comprising the following steps:
(1) introducing a repair template into a DNA-containing cell, which comprises the genetic alteration to be corrected, and
(2) introducing the nec-mRNA of claim 1 into the cell.

### Claim 20 (depends on 19)

The method of claim 19, wherein the cell is a lung cell and the introduction is realized by means of high pressure application of the repair template and the nec-mRNA into the lung.

### Claim 21 (depends on 11, 20)

The method of claim 20, wherein the nec-mRNA is the nec-mRNA of claim 11.

### Claim 22 (depends on 1)

A method for the correction of a genetic alteration on a DNA comprising the following steps:
(1) introducing a repair template into a living being having a genetically altered DNA to be corrected, and
(2) introducing the nec-mRNA of claim 1 into the living being.

### Claim 23 (depends on 22)

The method of claim 22, wherein the introduction is realized by means of high pressure application of the repair template and the nec-mRNA into the lung of the living being.

### Claim 24 (depends on 11, 23)

The method of claim 23, wherein the nec-mRNA is the nec-mRNA of claim 11.

### Claim 25 (depends on 1, 14)

The pharmaceutical composition of claim 14, which comprises the nec-mRNA of claim 1, wherein the nec-mRNA encodes a nuclease which is configured in such a way that it can bind upstream or downstream of the genetic alteration on the DNA.

### Claim 26 (depends on 25)

The pharmaceutical composition of claim 25, wherein the nec-mRNA is packed into a nanoparticle.

### Claim 27 (depends on 26)

The pharmaceutical composition of claim 26, wherein the nanoparticle is coated with chitosan.

### Claim 28 (depends on 27)

The pharmaceutical composition of claim 27, which further comprises a repair template.

### Claim 29 (depends on 1, 14)

The pharmaceutical composition of claim 14, which comprises the nec-mRNA of claim 1, wherein the nuclease is selected from the group consisting of: zinc-finger nucleases (ZFNs), transcription activator-like effector nucleases (TALEN), CRISPR/Cas9, and dimeric CRISPR RNA guided Fokl nucleases.

### Claim 30 (depends on 29)

The pharmaceutical composition of claim 29, wherein the nec-mRNA is packed into a nanoparticle.

### Claim 31 (depends on 30)

The pharmaceutical composition of claim 30, wherein the nanoparticle is coated with chitosan.

### Claim 32 (depends on 31)

The pharmaceutical composition of claim 31, which further comprises a repair template.

### Claim 33 (depends on 1, 14)

The pharmaceutical composition of claim 14, which comprises the nec-mRNA of claim 1, wherein the nec-mRNA is coupled to an aptamer.

### Claim 34 (depends on 33)

The pharmaceutical composition of claim 33, wherein the nec-mRNA is packed into a nanoparticle.

### Claim 35 (depends on 34)

The pharmaceutical composition of claim 34, wherein the nanoparticle is coated with chitosan.

### Claim 36 (depends on 35)

The pharmaceutical composition of claim 35, which further comprises a repair template.
